143 related articles for article (PubMed ID: 34351668)
1. Implications of a new element in the early diagnostic pathway for prostate cancer for rural Australians.
Macneil J; Wilkins R; Whelan C
Aust J Rural Health; 2021 Aug; 29(4):601-605. PubMed ID: 34351668
[TBL] [Abstract][Full Text] [Related]
2.
Lopci E; Saita A; Lazzeri M; Lughezzani G; Colombo P; Buffi NM; Hurle R; Marzo K; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Lista G; Cardone P; Castello A; Maffei D; Balzarini L; Chiti A; Guazzoni G; Casale P
J Urol; 2018 Jul; 200(1):95-103. PubMed ID: 29409824
[TBL] [Abstract][Full Text] [Related]
3. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
4. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
5.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
6. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Prostate Specific Membrane Antigen Targeted
Gorin MA; Rowe SP; Patel HD; Vidal I; Mana-Ay M; Javadi MS; Solnes LB; Ross AE; Schaeffer EM; Bivalacqua TJ; Partin AW; Pienta KJ; Szabo Z; De Marzo AM; Pomper MG; Allaf ME
J Urol; 2018 Jan; 199(1):126-132. PubMed ID: 28736318
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma.
Hoffmann MA; Buchholz HG; Wieler HJ; Müller-Hübenthal J; Trampert L; Richardsen I; Schreckenberger M
Health Phys; 2020 Jul; 119(1):141-147. PubMed ID: 32301863
[TBL] [Abstract][Full Text] [Related]
10. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
[TBL] [Abstract][Full Text] [Related]
11. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
12. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of
Fossati N; Scarcella S; Gandaglia G; Suardi N; Robesti D; Boeri L; Karnes RJ; Heidenreich A; Pfister D; Kretschmer A; Buchner A; Stief C; Battaglia A; Joniau S; Van Poppel H; Osmonov D; Juenemann KP; Shariat S; Hiester A; Nini A; Albers P; Tilki D; Graefen M; Gill IS; Mottrie A; Galosi AB; Montorsi F; Briganti A
J Urol; 2020 Aug; 204(2):296-302. PubMed ID: 32068488
[TBL] [Abstract][Full Text] [Related]
13. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
[TBL] [Abstract][Full Text] [Related]
14. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Tan N; Bavadian N; Calais J; Oyoyo U; Kim J; Turkbey IB; Mena E; Davenport MS
J Urol; 2019 Aug; 202(2):231-240. PubMed ID: 30829130
[TBL] [Abstract][Full Text] [Related]
15. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
16. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
McEwan L; McBean R; Yaxley J; Wong D
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
[TBL] [Abstract][Full Text] [Related]
17. Intraobserver and interobserver agreement for the interpretation of 68Ga-prostate-specific membrane antigen-I&T positron emission tomography/computed tomography imaging.
Gültekin A; Yaylalı O; Şengöz T; Yüksel D; Şahin B
Nucl Med Commun; 2019 Dec; 40(12):1250-1255. PubMed ID: 31584465
[TBL] [Abstract][Full Text] [Related]
18. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
[TBL] [Abstract][Full Text] [Related]
19.
Farolfi A; Gafita A; Calais J; Eiber M; Afshar-Oromieh A; Spohn F; Barbato F; Weber M; Ilhan H; Cervati V; Wetter A; Hadaschik B; Briganti A; Walz J; Pianori D; Fanti S; Haberkorn U; Herrmann K; Fendler WP
J Urol; 2019 Dec; 202(6):1174-1181. PubMed ID: 31233369
[TBL] [Abstract][Full Text] [Related]
20. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
